

CLEARBRIDGE HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 201001436C)

SECOND PARTIAL SETTLEMENT DEED - UPDATE

1. INTRODUCTION

The board of directors (the "**Board**" or the "**Directors**") of Clearbridge Health Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the announcements of the Company dated 27 March 2020, 3 April 2020, 26 May 2020, 24 December 2021, 24 June 2022, 23 September 2022, 28 February 2023, 10 March 2023, 22 September 2023, 4 October 2023, 22 November 2023 and 23 November 2023 (the "**Announcements**"). All capitalised terms used and not defined in this announcement shall have the same meanings ascribed to them in the Announcements. In particular, the Company refers to its announcement dated 23 November 2023 where it stated that CBSA had entered into a Second Partial Settlement Deed, pursuant to which Biolidics agreed that the Final Outstanding Debt of S\$1,338,750, shall be payable by Biolidics to CBSA by the Extended Final Repayment Date, being within two (2) days following the date of receipt of proceeds from the Investor or by 23 December 2023, whichever is earlier.

2. REPAYMENT AND RELEASE

The Company wishes to announce that CBSA has received the full amount of the Final Outstanding Debt on 30 November 2023 and in consideration of this, CBSA has entered into a deed of release of the Charged Shares in favour of Biolidics on the same day. Accordingly, no further amounts are owing by Biolidics to CBSA.

3. INTERESTS OF DIRECTORS AND CONTROLLING SHAREHOLDERS

As at the date of this announcement, save for Mr Chen Johnson, the Non-Executive and Non-Independent Chairman of the Company, who owns 0.49% of Biolidics, none of the Directors has any interest, direct or indirect, in any matters set out in this announcement, other than through their respective shareholdings in the Company. As at the date of this announcement, based on publicly available information and as far as the Directors are aware, the controlling shareholders of the Company do not have any interest, direct or indirect, in any matters set out in this announcement, other than through their respective shareholdings in the Company.

4. CAUTIONARY STATEMENT

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants, or other professional advisers if they are in doubt about the actions that they should take.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Executive Director and Chief Executive Officer

30 November 2023

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*